Analysts forecast that STERIS (NYSE:STE) will report sales of $709.63 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for STERIS’s earnings. The highest sales estimate is $711.20 million and the lowest is $707.00 million. STERIS reported sales of $681.19 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 4.2%. The business is scheduled to report its next earnings report on Tuesday, May 8th.
On average, analysts expect that STERIS will report full-year sales of $2.61 billion for the current year, with estimates ranging from $2.61 billion to $2.62 billion. For the next financial year, analysts anticipate that the firm will report sales of $2.73 billion per share, with estimates ranging from $2.73 billion to $2.74 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that that provide coverage for STERIS.
STERIS (NYSE:STE) last posted its quarterly earnings results on Wednesday, February 7th. The medical equipment provider reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.05. The business had revenue of $661.90 million during the quarter, compared to analyst estimates of $663.17 million. STERIS had a return on equity of 11.57% and a net margin of 9.42%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.98 earnings per share.
A number of research firms have recently issued reports on STE. Zacks Investment Research lowered STERIS from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Raymond James Financial reiterated a “market perform” rating and issued a $100.00 price objective on shares of STERIS in a report on Wednesday, January 3rd. Finally, Northcoast Research set a $102.00 price objective on STERIS and gave the company a “buy” rating in a report on Thursday, February 8th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $85.40.
In related news, CEO Walter M. Rosebrough, Jr. sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, March 12th. The stock was sold at an average price of $95.50, for a total value of $955,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Karen L. Burton sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $85.59, for a total value of $128,385.00. The disclosure for this sale can be found here. Insiders sold 78,415 shares of company stock worth $7,178,536 over the last quarter. 2.55% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Captrust Financial Advisors acquired a new position in STERIS during the fourth quarter worth $101,000. Meeder Asset Management Inc. lifted its stake in STERIS by 1,122.4% during the fourth quarter. Meeder Asset Management Inc. now owns 1,198 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 1,100 shares in the last quarter. YorkBridge Wealth Partners LLC acquired a new position in STERIS during the fourth quarter worth $113,000. Driehaus Capital Management LLC acquired a new position in STERIS during the fourth quarter worth $241,000. Finally, QS Investors LLC lifted its stake in STERIS by 36,250.0% during the fourth quarter. QS Investors LLC now owns 2,908 shares of the medical equipment provider’s stock worth $254,000 after purchasing an additional 2,900 shares in the last quarter. Hedge funds and other institutional investors own 89.40% of the company’s stock.
STE stock opened at $94.41 on Monday. The company has a quick ratio of 2.22, a current ratio of 2.82 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $8,008.81, a PE ratio of 25.11 and a beta of 1.12. STERIS has a 1 year low of $69.27 and a 1 year high of $96.43.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th were issued a $0.31 dividend. The ex-dividend date of this dividend was Tuesday, February 27th. This is a boost from STERIS’s previous quarterly dividend of $0.21. This represents a $1.24 dividend on an annualized basis and a yield of 1.31%. STERIS’s dividend payout ratio is currently 32.98%.
WARNING: “STERIS (STE) Expected to Post Quarterly Sales of $709.63 Million” was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.thelincolnianonline.com/2018/04/16/steris-ste-expected-to-post-quarterly-sales-of-709-63-million.html.
STERIS Company Profile
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.